E-mail Newsletter

  • Enter your e-mail address below to receive the "Patent Docs" e-mail newsletter.

Enter your email address:

Delivered by FeedBurner

Contact the Docs

Docs on Twitter


About the Authors

  • The Authors and Contributors of "Patent Docs" are patent attorneys and agents, many of whom hold doctorates in a diverse array of disciplines.

Disclaimer

  • "Patent Docs" does not contain any legal advice whatsoever. This weblog is for informational purposes only, and its publication does not create an attorney-client relationship. In addition, nothing on "Patent Docs" constitutes a solicitation for business. This weblog is intended primarily for other attorneys. Moreover, "Patent Docs" is the personal weblog of the Authors; it is not edited by the Authors' employers or clients and, as such, no part of this weblog may be so attributed. All posts on "Patent Docs" should be double-checked for their accuracy and current applicability.

Pharma-50-transparent_216px_red

Become a Fan

« Spectrum Pharmaceuticals Inc. v. Sandoz Inc. (Fed. Cir. 2015) | Main | Federal Circuit Denies En Banc Petition in Amgen v. Sandoz »

October 15, 2015

Comments

"The diplomats negotiating the Trans Pacific Partnership (TPP) agreement have done the seemingly impossible: they have kept the details of the draft agreement secret from the press and interested parties"
Not so, not in any way.
Some interested parties, like PhRMA and other trade associations, reportedly have been kept well informed; it's just other interested organizations, like consumer organizations, have been kept uninformed except by Wikileaks.
TPP gives all the appearance of an agreement negotiated by governments for the benefit of corporations, with consumers left to twist in the wind. But now that the negotiators have done their work, it is the legislators in the various countries who are going to have to approve it, and it is by no means clear that they will, whether in the US or elsewhere.

Point taken, Derek. We have revised

I know that this is primarily a biotech blog but I'm curious if you've seen any analysis on how the TPP will affect 101/Alice issues.

The plain language of the text would seem to allow for the types of data processing patents that have been invalidated en masse during the last few years, but it hasn't gotten any real attention.

The comments to this entry are closed.

October 2017

Sun Mon Tue Wed Thu Fri Sat
1 2 3 4 5 6 7
8 9 10 11 12 13 14
15 16 17 18 19 20 21
22 23 24 25 26 27 28
29 30 31